Drug Type Small molecule drug |
Synonyms |
Action inhibitors, antagonists |
Mechanism Aurora A inhibitors(Serine/threonine-protein kinase Aurora-A inhibitors), Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) + [6] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (European Union), Breakthrough Therapy (China) |
Molecular FormulaC20H19ClN6O |
InChIKeyDQFCVOOFMXEPOC-UHFFFAOYSA-N |
CAS Registry2230490-29-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Cholangiocarcinoma | Phase 3 | South Korea | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Portugal | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Netherlands | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Taiwan Province | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | France | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Belgium | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Poland | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | United States | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | Spain | 20 Dec 2023 | |
FGFR positive Cholangiocarcinoma | Phase 3 | United Kingdom | 20 Dec 2023 |
Phase 2 | Metastatic Cholangiocarcinoma MED12 mutation | ARID1A mutation | 55 | Tinengotinib 10 mg QD (A1: FGFR2 fusion(s) with primary progression on previous FGFR inhibitor (FGFRi)) | (cvwbcgulwm) = wmekmxulki hpfmnnraun (rvzeqrqlhu, 7.5 - 19.5) | Positive | 23 Jan 2025 | |
(A2: FGFR2 fusion(s) with progression after prior response to FGFRi) | (cvwbcgulwm) = caxivxcahi hpfmnnraun (rvzeqrqlhu, 9.6 - NR) | ||||||
Phase 1/2 | 31 | Tinengotinib + Atezolizumab | (dbdsdozvmi) = izdnzcnanr kxxcruebfe (nmtnflkmsh ) View more | Positive | 07 Dec 2024 | ||
Tinengotinib + Atezolizumab (cholangiocarcinoma) | (dbdsdozvmi) = uhsunqdjsn kxxcruebfe (nmtnflkmsh ) View more | ||||||
Phase 1/2 | Solid tumor | | | 53 | (oucebamclx) = llzaswzopq uqqvrrutiw (hfxuembeyq ) View more | Positive | 05 Apr 2024 | ||
(prior FGFR inhibitor) | (oucebamclx) = tdsyfxfcgm uqqvrrutiw (hfxuembeyq ) View more | ||||||
Phase 1/2 | 30 | (wplkwhtxxn) = mwijbesxod fpdedejwsu (idybxgompi ) View more | - | 25 Jan 2024 | |||
Phase 2 | 48 | (FGFR2 fusion/rearrangement) | (gxvjgqoesc) = xzmrcsytog wbihjnhoqz (rpkslrkccb ) View more | Positive | 18 Jan 2024 | ||
Tinengotinib 10 mg (primary progression on previous FGFR inhibitor) | (gspwcueroc) = dfqfqajevv uuclfdjfee (tvnofqimpw ) | ||||||
PRNewswire Manual | Phase 3 | Triple Negative Breast Cancer | Hormone receptor positive HER2 negative breast cancer | | | ... View more | - | (HR+/HER2- BC) | (tjvbhirqos) = jqeaioufop mtoowwpkzb (pkrzrtoedk ) View more | Positive | 07 Dec 2023 |
(TNBC) | (tjvbhirqos) = csnhdxwjdz mtoowwpkzb (pkrzrtoedk ) View more | ||||||
Phase 1/2 | Advanced Malignant Solid Neoplasm FGFR2 alteration | 33 | (zetmxvdbwy) = iywijqllqr ebktvhjjkb (elvhswmkic ) View more | Positive | 23 Oct 2023 | ||
(measurable target lesions) | (shlwbengyr) = dkevlnrpxn tozjparxdf (hniqidbaer ) View more | ||||||
Phase 1/2 | Bile Duct Neoplasms FGFR2 | 73 | (gxsnxnexvv) = bccxlzoual rpeamihrux (onghpglxfd ) View more | Positive | 21 Oct 2023 | ||
(FGFR2 alteration who received prior FGFR) | (gxsnxnexvv) = fzsszblepf rpeamihrux (onghpglxfd ) View more | ||||||
Phase 1/2 | 157 | (12 mg QD) | (iwjiamwwto) = In 108 efficacy-evaluable pts of monotherapy arms were 60% slcfcgsion (ravoralvez ) View more | Positive | 31 May 2023 | ||
Phase 2 | Metastatic Cholangiocarcinoma FGFR alteration | FGFR Wild-type | FGFR2 fusion | 25 | (elxhydozdp) = Most frequently occurred G3/4 AEs were hypertension in 6 (24%) pts, including 5 (20%) with G3 and 1 (4%) with G4, G3 fatigue in 2 (8%) and G3 neutrophil count decreased in 2 (8%) pts dicxflzkfg (suyeccpafr ) View more | Positive | 24 Jan 2023 | ||
(FGFR2 fusion/rearrangement pts) |